Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKMBSJ)

Drug Name

NM-9405 Drug Info

Synonyms

Humanized Yalciomab (rheumatoid arthritis), Novelmed Therapeutics Inc; H-Yalciomab (rheumatoid arthritis), NovelmedTherapeutics Inc

Indication

Disease Entry	ICD 11	Status	REF
Rheumatoid arthritis	FA20	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tumor necrosis factor receptor type I (TNF-R1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VB-111	DMX04CA	Malignant glioma	2A00.0	Phase 3	[2]
Drug 2862277	DM8WU3O	Acute lung injury	NB32.3	Phase 2	[1]
AVX-470	DMAKD0I	Inflammatory bowel disease	DD72	Phase 1	[3]
GSK1995057	DMC14KV	Adult respiratory distress syndrome	CB00	Phase 1	[4]
Anti-IFN gamma	DMXI185	Alopecia	ED70	Terminated	[3]
TNFR1 NAM	DMPTQEG	Multiple sclerosis	8A40	Investigative	[1]
TNFmab	DM4T0ZF	Rheumatoid arthritis	FA20	Investigative	[3]
ADS-0101	DMP7IS0	Chronic obstructive pulmonary disease	CA22	Investigative	[1]
Recombinant human TNF receptor	DMLYQWV	Arthritis	FA20	Investigative	[3]
TNFcept	DMAGI7K	Rheumatoid arthritis	FA20	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor necrosis factor receptor type I (TNF-R1)	TTG043C	TNR1A_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870).
2	Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007.
3	Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65.
4	Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha receptor 1. J Clin Immunol. 2013 Oct;33(7):1192-203.